Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions
Press release – No. 6 / 2023 Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396...
News
Enterin Presents Data Demonstrating Strong Benefit of ENT-03 on Body Weight, Adiposity and Blood Glucose Vs. Semaglutide in a Diet Induced Obesity Mouse Model
Data presented at the American Diabetes Association 83rd Scientific SessionsPHILADELPHIA, June 24, 2023 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held,...
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D
– Data from two ongoing clinical trials in people living with chronic hepatitis B infection suggest the combination of an...
89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine
– Published data showed consistent and significant reductions in triglycerides, atherogenic lipoproteins and liver fat, and pegozafermin’s favorable safety and...
Data from 89bio’s ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Liver Congress
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant changes on...
Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association
Daix (France), Long Island City (New York, United States), June 24, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a...
Biomea Fusion Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association (ADA) 83rd Scientific Sessions; 100 mg Cohort 3 Demonstrated a 90% Response Rate and 70% Maintained or Improved Time in (Normal Glucose) Range, While Off-Treatment
Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an...
Carmot Therapeutics Highlights Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 83rd American Diabetes Association Scientific Sessions
– Once-weekly administration of CT-388 delivers clinically meaningful weight loss and metabolic control with a favorable tolerability profile over a...
XORTX Reminds Shareholders to Vote ahead of the Proxy Voting Deadline for the Company’s Upcoming Annual and Special Meeting of Shareholders
The proxy voting deadline for XORTX shareholders to vote their proxies is 10:00 a.m. (Calgary time) on Monday, June 26,...
Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development
First late-stage study will be a Phase 2b dose optimization study, with extension to run in parallel with next-stage Phase...
XOMA Added to the Russell 2000® and Russell 3000® Indexes
EMERYVILLE, Calif., June 23, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced it has been...
Kane Biotech Announces Issuance of Restricted Share Units
WINNIPEG, Manitoba, June 23, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF), (the “Company” or “Kane Biotech”), today announces...
Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906)
Press Release No. 5 / 2023 Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer...
Biosenta Announces Entering Into of Agreement to Terminate Joint Venture
TORONTO, June 23, 2023 (GLOBE NEWSWIRE) -- Biosenta Inc. (the “Company” or “Biosenta”) (CSE: ZRO) is pleased to announce that...
Enochian BioSciences Inc. Announces Adjournment of 2023 Annual Stockholder Meeting
LOS ANGELES, June 23, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc., a company developing gene-modified cell immunotherapies for...
ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023
ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held...
AC Immune Holds Annual General Meeting of Shareholders
AC Immune Holds Annual General Meeting of Shareholders Shareholders approved all resolutions as proposed by the Board of Directors Lausanne,...
Cronos Group Inc. Announces Results of 2023 Annual Meeting of Shareholders
TORONTO, June 23, 2023 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) announces that at...
INOVIO Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
Plymouth Meeting, Pa., June 23, 2023 (GLOBE NEWSWIRE) -- INOVIO (NASDAQ:INO) has released the following pursuant to an order of...
Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ARLINGTON, Mass., June 23, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock...